MiMedx Group (MDXG) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Voting matters and shareholder proposals
Election of seven directors, with each nominee recommended for approval by the board.
Advisory vote on executive compensation is presented for shareholder approval.
Ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Proxies may vote on other business that may properly come before the meeting or any adjournment.
Board of directors and corporate governance
Seven director nominees are listed for election at the annual meeting.
Executive compensation and say-on-pay
Advisory approval of executive compensation is included as a voting item.
Partial view of Summaries dataset, powered by Quartr API
Latest events from MiMedx Group
- Sanara MedTech acquisition for $350M targets $400M+ 2027 revenue and 20%+ EBITDA margin.MDXG
Q2 2026 & M&A announcement - Strong growth, product innovation, and regulatory tailwinds position the business for long-term success.MDXG
Cantor Global Healthcare Conference 2025 - Regulatory reform and strategic expansion drive optimism for growth amid reimbursement challenges.MDXG
2024 Cantor Fitzgerald Global Healthcare Conference - Directors elected, compensation and auditor ratified, with strategic focus on surgical growth and cost control.MDXG
AGM 2026 - Strong sales growth, new product launches, and robust governance highlighted in 2025.MDXG
Proxy filing - Q1 2026 sales fell 33% as wound care plunged 60% and surgical rose 13%, prompting cost cuts.MDXG
Q1 2026 - Record revenue and EBITDA in 2025; surgical growth offsets wound care disruption.MDXG
Q4 2025 - Q2 net sales up 7.3% to $87.2M; adjusted EBITDA margin 23%; outlook remains strong.MDXG
Q2 2024 - Strong growth, innovation, and Medicare reform position MiMedx for expanded market leadership.MDXG
TD Cowen 45th Annual Healthcare Conference